文献速递腹部技术与安全MR

钆贝葡胺增强MRI定量信息可预测单发肝细胞癌增殖亚型:一项多中心回顾性研究

Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
PubMed 文献 · Eur Radiol · 2023-09-11

该多中心回顾性研究纳入218例经手术病理证实的单发肝细胞癌患者,评估钆贝葡胺增强MRI肝胆期病灶-肝脏对比增强比(LLCER)与病灶-肝脏对比(LLC)预测增殖亚型的价值。LLCER是增殖型HCC的独立预测因子(OR 0.015),AUC 0.812,优于LLC、AFP>100 ng/ml、卫星结节及环形动脉期高强化;LLCER<-4.59%者增殖型HCC发生率显著更高,且LLCER为总生存的独立预测因子(HR 0.070)。

要点

  • 肝胆期LLCER是单发HCC增殖亚型的独立预测因子,AUC 0.812。
  • LLCER<-4.59%者增殖型HCC发生率显著高于LLCER≥-4.59%者。
  • LLCER预测增殖型HCC的能力优于LLC、AFP>100 ng/ml、卫星结节及环形动脉期高强化。

核心结论

  • 钆贝葡胺增强MRI肝胆期定量参数LLCER可预测单发HCC的增殖亚型,准确度中等偏高,并可作为总生存的独立预测因子。

研究设计与样本

  • 多中心回顾性研究,纳入218例经手术切除并病理证实的单发HCC患者,均行钆贝葡胺增强MRI,于肝胆期测量LLCER和LLC,采用logistic回归评估增殖型HCC的危险因素,ROC曲线评估预测能力,Cox比例风险回归模型评估生存预后因素。

诊断标准与关键数值

  • LLCER预测增殖型HCC的AUC为0.812(95%CI 0.748-0.877),高于LLC、AFP>100 ng/ml、卫星结节及环形动脉期高强化(均p≤0.001);LLCER<-4.59%者增殖型HCC发生率显著高于LLCER≥-4.59%者;LLCER预测增殖型HCC的OR为0.015(95%CI 0.008-0.022,p<0.001);LLCER预测总生存的HR为0.070(95%CI 0.015-0.324,p=0.001)。

临床应用与阅片要点

  • 作者认为钆贝葡胺增强MRI定量信息可提供HCC亚型的关键信息,可能有助于设计靶向治疗或免疫治疗等新治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the value of quantitative parameters derived from gadobenate dimeglumine-enhanced magnetic resonance imaging (MRI) for predicting molecular subtype of hepatocellular carcinoma (HCC) and overall survival.

METHODS: This multicenter retrospective study included 218 solitary HCC patients who underwent gadobenate dimeglumine-enhanced MRI. All HCC lesions were resected and pathologically confirmed. The lesion-to-liver contrast enhancement ratio (LLCER) and lesion-to-liver contrast (LLC) were measured in the hepatobiliary phase. Potential risk factors for proliferative HCC were assessed by logistic regression. The ability of LLCER and LLC to predict proliferative HCC was assessed by the receiver operating characteristic (ROC) curve. Prognostic factors were evaluated using the Cox proportional hazards regression model for survival outcomes.

RESULTS: LLCER was an independent predictor of proliferative HCC (odds ratio, 0.015; 95% confidence interval [CI], 0.008-0.022; p < 0.001). The area under the ROC curve was 0.812 (95% CI, 0.748-0.877), higher than that of LLC, alpha-fetoprotein > 100 ng/ml, satellite nodules, and rim arterial phase hyperenhancement (all p ≤ 0.001). HCC patients with LLCER < -4.59% had a significantly higher incidence of proliferative HCC than those with the LLCER ≥ -4.59%. During the follow-up period, LLCER was an independent predictor of overall survival (hazard ratio, 0.070; 95% CI, 0.015-0.324; p = 0.001) in HCC patients.

CONCLUSIONS: Gadobenate dimeglumine-enhanced quantitative parameter in the hepatobiliary phase can predict the proliferative subtype of solitary HCC with a moderately high accuracy.

CLINICAL RELEVANCE STATEMENT: Quantitative information from gadobenate dimeglumine-enhanced MRI can provide crucial information on hepatocellular carcinoma subtypes. It might be valuable to design novel therapeutic strategies, such as targeted therapies or immunotherapy.

KEY POINTS: • The lesion-to-liver contrast enhancement ratio (LLCER) is an independent predictor of proliferative hepatocellular carcinoma (HCC). • The ability of LLCER to predict proliferative HCC outperformed lesion-to-liver contrast, alpha-fetoprotein > 100 ng/ml, satellite nodules, and rim arterial phase hyperenhancement. • HCC patients with LLCER < -4.59% had a significantly higher incidence of proliferative HCC than those with the LLCER ≥ -4.59%.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ding F, Huang M, Ren P, et al. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study. Eur Radiol. 2023. PMID: 37691080. doi:10.1007/s00330-023-10227-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。